Yun Zhong
Stock Analyst at Wedbush
(0.52)
# 3,811
Out of 4,829 analysts
30
Total ratings
26.92%
Success rate
-16.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $181 → $212 | $156.38 | +35.57% | 1 | May 2, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $13.89 | +8.03% | 1 | Apr 1, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $45.31 | +54.49% | 2 | Mar 28, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | n/a | $3.44 | - | 1 | Mar 12, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $4 | $0.30 | +1,233.33% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $40.60 | +79.80% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $3.74 | +220.86% | 1 | Nov 5, 2024 | |
| AVXL Anavex Life Sciences | Maintains: Buy | $35 → $28 | $8.53 | +228.25% | 2 | Feb 9, 2023 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | n/a | $2.24 | - | 2 | Feb 2, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $14 → $16 | $6.23 | +156.82% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $36.93 | +333.25% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $7.19 | +386.79% | 1 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 | $3.46 | +20,131.21% | 2 | Jul 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $13.05 | +252.49% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.52 | +297.61% | 1 | May 5, 2021 |
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $181 → $212
Current: $156.38
Upside: +35.57%
Keros Therapeutics
Apr 1, 2025
Reiterates: Neutral
Price Target: $15
Current: $13.89
Upside: +8.03%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $45.31
Upside: +54.49%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: n/a
Current: $3.44
Upside: -
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.30
Upside: +1,233.33%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $40.60
Upside: +79.80%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $3.74
Upside: +220.86%
Anavex Life Sciences
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $8.53
Upside: +228.25%
Taysha Gene Therapies
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.24
Upside: -
Amicus Therapeutics
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $6.23
Upside: +156.82%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $36.93
Upside: +333.25%
Nov 1, 2022
Initiates: Buy
Price Target: $35
Current: $7.19
Upside: +386.79%
Jul 1, 2021
Downgrades: Hold
Price Target: $700
Current: $3.46
Upside: +20,131.21%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $13.05
Upside: +252.49%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.52
Upside: +297.61%